Tackling Precision Medicine with a New Kind of Decision Support

When Clynt Taylor joined Intervention Insights two years ago as CEO, the Burlington, MA-based company had already developed a platform that was being used to inform the results of molecular tests in oncology. At that time the platform was designed to take results from a molecular test and supplement that information with levels of evidence to help doctors determine which available treatment option had the highest level of evidence to support it. It was a good idea, Taylor says, but when the company started in 2011 the need for that service was greater than it is today. It wasn't long before Taylor recognized that the real unmet need was to help doctors determine who should be tested, what they should be tested for, what labs should be used and what products are offered by those labs, what will the patient's insurance company pay for – and perhaps more importantly, what will it not pay for – and if three labs qualify can the doctor use the one that they prefer? And on top of all that, there was a need to push the order automatically because about half of the orders placed today are placed on paper, he told MD+DI. From there, Taylor spent a lot of time in oncology practices asking providers what their biggest challenge is for using precision medicine and the consensus was that when the lab results come back doctors have a hard time standardizing the approach they use because every lab looks at the information different...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news